420 Investor Conversation with Dr. Michelle Sexton
Abattis Bioceuticals (ATTBF) owns a 51% stake in Washington-based PhytaLab, which is awaiting certification approval (on a provisional basis). Dr. Michelle Sexton is the CSO and acting CEO of PhytaLab. The conversation covered Dr Sexton's background, the nature of PhytaLab, how Dr. Sexton connected with Abattis and the nature of their partnership, the certification process, the competitive landscape and the issues surrounding geographic expansion. The conversation was about 17 minutes.
For more info on PhytaLab: http://phytalab.com/
Recent free content from Cannabis Analyst
-
Marketfy Has Evolved - We're Moving to a New Platform!
— 3/06/24
-
420 Investor Weekly Review 12/23/22
— 12/26/22
-
420 Investor Weekly Review 12/16/22
— 12/16/22
-
420 Investor Weekly Review 12/09/22
— 12/09/22
-
420 Investor Weekly Review 12/02/22
— 12/02/22
